CROI 2015 Program and Abstracts

Abstract Listing

Poster Abstracts

1052 National Estimates of Life Expectancy After HIV Diagnosis: US HIV Surveillance Data Azfar-e-Alam Siddiqi ; H. Irene Hall; Xiaohong Hu; Ruiguang Song US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US Background: Previous life expectancy estimates have shown that introduction of highly active antiretroviral therapy has improved the life expectancy after HIV diagnosis, in the United States, from 1996 to 2005. We updated the life expectancy estimates for the years 2008–2011 using surveillance data from all 50 states and DC. Methods: We used U.S. national HIV surveillance data (adults and adolescents with age at HIV diagnosis ≥ 13 years) to estimate life expectancy after an HIV diagnosis following the life table approach. Survival within one year, or more than one year after HIV diagnosis was estimated separately and then used to estimate overall life expectancy. Separate sex, race/ethnicity, disease severity (stage 3 vs stages 0–2), and risk factor based average life expectancy estimates were also generated. The data were adjusted for reporting delays and missing risk factors. The differences reported are relative differences of at least 5%. Results: From year 2008 to 2011, the average life expectancy after HIV diagnosis increased from 25.4 to 28.9 years. Life expectancy was longer for males than for females; improved less for females (females: 23.7–26.4 and males: 26.0–29.6) and showed increasing differences between life expectancies for males and females (2008: 2.3 and 2011: 3.3 years). In 2011, life expectancy for white females was shortest, followed by black females and then Hispanic females. By risk factors, shortest life expectancy was in male injection drug users (IDU), followed by female IDUs and male heterosexuals.

Table 1: Life expectancy of persons diagnosed with HIV, years 2008–2011; overall and by sex and race/ethnicity. Conclusions: Life expectancy for females of each race/ethnicity group was less than that for males of the same race/ethnicity. Greater disparities in life expectancies by race/ ethnicity were seen in males than in females. Disparities in life expectancy by sex and race/ethnicity persist and should be addressed. 1053 Age-Related Morbidities Among HIV-Infected Adults From 2000 to 2010 CheriseWong 1 ; Stephen J. Gange 1 ; Michael A. Horberg 2 ; Gregory D. Kirk 1 ; Anita Rachlis 3 ; John Gill 4 ; Jennifer E.Thorne 1 ; Robert Hogg 5 ; James J. Goedert 6 ; Keri N. Althoff 1 1 Johns Hopkins University, Baltimore, MD, US; 2 Mid-Atlantic Permanente Research Institute, Rockville, MD, US; 3 University of Toronto Sunnybrook Research Institute, Toronto, Canada; 4 University of Calgary, Alberta Health Services, Calgary, Canada; 5 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 6 National Cancer Institute (NCI), Rockville, MD, US Background: Among HIV-infected individuals on antiretroviral therapy, conditions typically associated with aging in the general population are emerging as significant sources of concern. Understanding age-related comorbidity occurrence is increasingly important to inform interventions for persons aging with HIV and studies of multimorbidity. The objective of this study was to estimate incidence of hypertension, diabetes, chronic kidney disease (CKD), and anemia in HIV-infected adults in care. Methods: Data analyzed were from 19 HIV observational cohort studies within the North American AIDS Cohort Collaboration on Research and Design from 2000-2010. The definitions of the 4 morbidities examined were, hypertension: prescription of anti-hypertensive medication, or 2 systolic measures ≥ 140 mmHg or diastolic measures ≥ 90 mmHg within 9 months; diabetes: HbgA1c ≥ 6.5%, or prescription of diabetes-specific medications, or prescription of diabetes-related medications with a history of diabetes diagnosis; CKD: 2 values of eGFR<60 mL/min/1.73 m 2 (per CKD-Epi equation) >90 days apart without an intervening normal value; anemia: 1 measure of hemoglobin<13 g/dL (men) or <12 g/dL (women). Prevalent cases were excluded and participants were required to contribute >1 visit during 2000-2010. Incidence rates (IR) per 100 person-years, adjusted ratios (aIRR) and 95% confidence intervals (95% CI) were estimated using Poisson regression models, adjusted for time-varying age, sex, race, history of injection drug use (IDU), cohort, time-varying CD4 count (<200, 200-349, 350-499, ≥ 500 cells/mm 3 ) and time-varying viral load ( ≤ 200, >200 copies/mL), and calendar year. Results: For each outcome, more than 5,000 HIV-infected adults were included in analyses, and contributed a range of 18,494 – 150,662 person-years. There were 6,098 hypertension, 791 diabetes, 1,894 CKD, and 9,039 anemia incident events. Overall, aIRRs showed an increased risk of comorbidity occurrence among older groups, as compared with individuals <40 years of age (Table 1). An increased risk for each comorbidity except diabetes was observed when comparing CD4 counts <200 to CD4 >500.

Poster Abstracts

615

CROI 2015